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Abstract
Synthetic splice-switching oligonucleotides (SSOs) target nuclear pre-mRNA molecules to change exon
splicing and generate an alternative protein isoform. Clinical trials with two competitive SSO drugs are
underway to treat Duchenne muscular dystrophy (DMD). Beyond DMD, many additional therapeutic appli-
cations are possible, with some in phase 1 clinical trials or advanced preclinical evaluation. Here, we present an
overview of the central factors involved in developing therapeutic SSOs for the treatment of diseases. The
selection of susceptible pre-mRNA target sequences, as well as the design and chemical modification of SSOs
to increase SSO stability and effectiveness, are key initial considerations. Identification of effective SSO target
sequences is still largely empirical and published guidelines are not a universal guarantee for success. Speci-
fically, exon-targeted SSOs, which are successful in modifying dystrophin splicing, can be ineffective for
splice-switching in other contexts. Chemical modifications, importantly, are associated with certain charac-
teristic toxicities, which need to be addressed as target diseases require chronic treatment with SSOs. Moreover,
SSO delivery in adequate quantities to the nucleus of target cells without toxicity can prove difficult. Last, the
means by which these SSOs are administered needs to be acceptable to the patient. Engineering an efficient
therapeutic SSO, therefore, necessarily entails a compromise between desirable qualities and effectiveness.
Here, we describe how the application of optimal solutions may differ from case to case.
Introduction
Splice-switching oligonucleotides (SSOs) were firstdescribed for correction of aberrant splicing in human b-
globin pre-mRNAs (Dominski and Kole, 1993), but have
progressed furthest in the treatment of Duchenne muscular
dystrophy (DMD). For this indication, two separate SSO
compounds, eteplirsen (AVI-4658; Sarepta Therapeutics,
Cambridge, MA) and drisapersen (PRO051/GSK2402968;
Prosensa/GlaxoSmithKline [GSK]), are competing in clini-
cal trials (Arechavala-Gomeza et al., 2012). Both therapeutic
SSOs are intended to cause skipping of dystrophin exon
51, which restores the open reading frame in 13% of DMD
mutations. These SSOs cover the same target sequence
(with eteplirsen containing 10 more nucleotides), but differ
in their chemical composition as eteplirsen is based on
phosphoramidate morpholino chemistry, and drisapersen is
based on phosphorothioated 2¢-O-methyl RNA chemistry. A
number of SSOs (Prosensa, 2013) targeting different exons
within the dystrophin gene are also in early clinical (PRO044,
PRO045, and PRO053, skipping of exons 44, 45, and 53,
respectively) and preclinical (PRO052 and PRO055, for ex-
ons 52 and 55) development.
The success of the early DMD exon-skipping trials has
also inspired a number of other therapeutic applications of
SSOs, foremost among them ISIS-SMNRx for the treatment
of spinal muscular atrophy (SMA). This SSO has rapidly
progressed to phase 2 clinical trials for type I SMA in in-
fants because of the promising data from the initial dose-
ranging study (Swoboda et al., 2013). Type I SMA leads to
a severely reduced life span of less than 2 years, and there
are currently no other treatment options. More therapeutic
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applications are still in the translational stages with some
in vivo proof-of-principle data available.
Here, we briefly analyze clinical developments and the
various available oligonucleotide chemical modifications. It
appears that toxicity of SSOs is largely determined by these
chemical modifications, with sequence-dependent toxicity
being less of an issue (Aartsma-Rus and Muntoni, 2013).
Lessons learned in these early clinical trials will be ap-
plicable to the further development of therapeutics still in
the translational stage and, it is hoped, lead to a shortened
and simplified clinical approval pathway. However, it is
becoming clear that the lessons learned from the special
case of DMD, where the aim is to cause exon skipping in a
low-expressed dystrophin pre-mRNA, may not be entirely
typical. We propose that there is a relationship between
target pre-mRNA expression levels and required oligonu-
cleotide concentration in the nucleus for effective splicing
manipulation and discuss the ensuing necessity for tissue-
specific delivery reagents in more detail.
Clinical Development of SSOs to Treat Duchenne
Muscular Dystrophy
DMD is an X-linked, inherited, and progressive muscle-
wasting disease afflicting 1 in 3500 newborn boys, typically
diagnosed between the ages of 3 and 5 years. It is caused by
specific gene mutations in dystrophin, an essential part of the
dystrophin-associated glycoprotein complex that connects the
actin cytoskeleton to the surrounding extracellular matrix via
the cell membrane, providing vital structural support (Cohn
and Campbell, 2000). Loss of dystrophin function results in
muscle degeneration and replacement with fibro-adipose tis-
sue, leading to severe disability, loss of ambulation, and
eventually an early death due to respiratory or cardiac failure.
Dystrophin gene mutations cause mostly deletions of
certain exons resulting in frameshifts in the exons that fol-
low, premature termination, and thus loss of protein func-
tion. SSOs can restore the open reading frame by skipping
additional exons to get back into frame. This leads to the
expression of internally truncated but mostly functional
dystrophin protein, similar to the isoforms found in the
milder Becker muscular dystrophy (Koenig et al., 1989).
The clinical development of eteplirsen and drisapersen
has been well reviewed (Arechavala-Gomeza et al., 2012;
Kole and Leppert, 2012; Koo and Wood, 2013) and there-
fore we present only the most up-to-date data available,
which has not been covered in these sources. GSK (Brent-
ford, UK) and Prosensa (Leiden, The Netherlands) reported
that the primary end point of improvement in the 6-minute
walk test (6MWT) was not met in a 2-year phase 3 study
(NCT01254019; www.clinicaltrials.gov/) of drisapersen (6mg/
kg/week). Although there was a slight 6MWT increase, this
was not significant and secondary end points such as the
North Star Ambulatory Assessment also failed to show
significant improvement. However, serum creatine phos-
phokinase, which is abnormally high in patients with DMD,
was significantly decreased, indicating reduced stress dam-
age of the muscle fibers (GlaxoSmithKline, 2013). In Jan-
uary 2014, Prosensa announced that it had regained all
rights to drisapersen from GSK (Prosensa, 2014).
Sarepta Therapeutics reported 96-week data from
their phase 2b open-label extension study of eteplirsen
(NCT01540409). These demonstrated stabilization in the
6MWT with a difference of 68m between the combined
30- and 50-mg/kg/week treatment groups and the placebo/
delayed treatment group, which had shown a decline up to
36 weeks after the trial started. The boys in the delayed
treatment group were crossed over into the treatment
groups at week 24 and showed stabilization of 6MWT
values at week 36 (Mendell et al., 2013). Further data at
120 weeks demonstrate that this stabilization still persists
(Sarepta Therapeutics, 2014a). Accelerated U.S. Food and
Drug Administration (FDA) approval on the back of these
data was denied because of concerns about the discon-
nection between increases in dystrophin levels and clinical
outcome in the drisapersen trial and the lack of a validated
quantitative assay for dystrophin. Another concern was the
low number of trial participants (only 12 were enrolled in
total). The FDA also expressed concern about the 6MWT
as an appropriate end point and stated their belief that a
placebo-controlled trial would be necessary to prove effi-
cacy. However, the FDA provided a guidance letter sug-
gesting that they would consider accelerated approval
under certain conditions and Sarepta Therapeutics has
stated its intent to submit a New Drug Application by the
end of 2014 (Sarepta Therapeutics, 2014b).
Taken together, these setbacks may have negative im-
plications for the whole field of therapeutic SSOs, even
though Prosensa has reiterated its commitment to exon-
skipping therapies for DMD and Sarepta Therapeutics is
continuing development of eteplirsen.
Clinical Development of SSOs to Treat Spinal
Muscular Atrophy
On the other hand, an SSO for the treatment of spinal
muscular atrophy (SMA) has generated positive data in a
phase 1 clinical trial. SMA, an autosomal recessive disease
affecting 1 in 6000 newborn children, is caused by muta-
tions in the survival of motor neuron gene 1 (SMN1) and
results in progressive loss of motor neurons in the spinal
cord and subsequent atrophy of voluntary muscles. Clinical
severity depends on naturally occurring exon 7 inclusion
levels in the almost identical SMN2 gene and the number of
copies of SMN2. In SMN2, a C >T transition in an exon 7
splicing enhancer site normally results in an unstable exon
7-deleted isoform and insufficient levels of full-length iso-
form (Khoo and Krainer, 2009; Fig. 1A). However, effective
SMN2 exon 7 inclusion can be achieved by blocking an
intronic splicing silencer in the 5¢ region of intron 7 (ISS-
N1; Singh et al., 2006; Hua et al., 2008) with SSOs. On the
basis of successful mouse studies (Hua et al., 2010, 2011;
Passini et al., 2011) a candidate SSO was quickly moved
into a phase 1 clinical trial by Isis Pharmaceuticals (Carls-
bad, CA), because validation of pharmacological efficacy in
nonhuman primates was not possible as they lack SMN2.
In the phase 1 trial (NCT01494701), direct injection of a
single 9-mg dose of ISIS-SMNRx into the intrathecal space
resulted in broad distribution in the central nervous system
and some motor function improvement in children with
SMA (Swoboda et al., 2013). Preclinical and mouse data
(Hua et al., 2010) on SSO persistence and continued effi-
cacy in the spinal cord suggest that infrequent dosing every
6–9 months may be enough for a sustained therapeutic
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effect. However, systemic SSO delivery may be needed to
alleviate cardiac pathology and to increase peripheral motor
neuron function and consequently survival (Hua et al., 2011;
Porensky et al., 2012). Thus, it may be necessary to ad-
minister the SSO both systemically and directly into the
intrathecal space, with the former at more frequent intervals.
Moreover, in mice there is a tight therapeutic window ( £ 28
days from birth) during which SMN expression is required
to overcome early death (Foust et al., 2010; Le et al., 2011).
As yet, it is unclear how long such a therapeutic window
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FIG. 1. Mechanisms of splice modulation. (A) Spinal muscular atrophy (SMA) is caused by loss of full-length SMN1
expression (top). SMN2, a near-identical copy of SMN1, has 11 nucleotide changes, among them a C-to-T transition in exon
7. This results in skipping of exon 7 in the majority of transcripts (middle) and leads to rapid degradation of the skipped
mRNA isoform. Splice-switching oligonucleotide (SSO) binding to an intronic splice silencer (ISS) site, which is re-
sponsible for repressing exon 7 inclusion in both SMN1 and SMN2, can significantly increase the level of SMN2 full-length
transcripts. (B) Expression of the putative atheroprotective APOB87 isoform can be induced by skipping exon 27, leading to
a frameshift and premature termination codon (PTC) in exon 28. (C) SSOs blocking the exon 13–intron 13 junction of
kinase insert domain receptor (KDR) induce inclusion of intron 13, resulting in the use of a stop codon and polyadenylation
site within intron 13 and thus a truncated protein. mbKDR, membrane-bound KDR; sKDR, soluble KDR. (D) The switch
from the STAT3a to the STAT3b isoform can be mediated by SSOs blocking the splice acceptor site in exon 23, forcing the
use of an alternative acceptor site, which leads to a premature termination codon (PTC). (E) Insertion of SINE-VNTR-Alu
(SVA) containing a strong 3¢ acceptor site into the FKTN gene results in Fukuyama muscular dystrophy (FCMD). A weak 5¢
donor site at the beginning of exon 10 is activated, causing partial exclusion of exon 10, including the FKTN stop codon.
The abnormal splicing also excludes part of the SVA sequence, resulting in a stop codon. Blocking the 3¢ acceptor site in
SVA with SSOs restores the normal splicing pattern and thus use of the FKTN stop codon, while the SVA sequence is still
contained within the mRNA. Color images available online at www.liebertpub.com/hum
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would be in humans, but the data from mouse studies cer-
tainly emphasize that early treatment is better.
Taking this into account, together with the promising
results from the first SMA clinical study, Isis Pharmaceu-
ticals has already initiated a phase 2 clinical trial
(NCT01839656) in infants with type I SMA, the most severe
form of the disease; patients have an expected life span of
less than 2 years. The study is expected to run for 1 year
with three intrathecal injections at two different dosing
levels and will enroll 20 infants up to 210 days of age. All
enrolled patients will be treated with active drug. Interim
data from this trial and the phase 1 extension study are
extremely promising and show dose- and time-dependent
improvements that correlate with increased levels of SMN
protein (Isis Pharmaceuticals, 2014a,b). Given the disease
severity and absence of other treatment options, it is hoped
that this SSO will be successful and thereby also provide a
much-needed boost to the field of therapeutic splicing
modulation following the setbacks in the DMD field.
Additional Therapeutic Applications
As enumerated in Table 1, several additional SSO thera-
peutics have progressed into the in vivo proof-of-principle
stage, validating diverse concepts of splicing modulation in-
duced by oligonucleotides. The number of such published
studies is increasing each year, and thus we make no claim to
be exhaustive. Here, we concentrate on select in vivo studies
that we find particularly innovative, as information about other
in vitro and in vivo studies can be found in van Roon-Mom and
Aartsma-Rus (2012) or Havens and colleagues (2013).
A novel therapeutic concept in this domain is to generate
a desirably functional protein isoform by splice switching.
We have used this method in apolipoprotein B (APOB) to
treat familial hypercholesterolemia, a genetic disease char-
acterized by high levels of low-density lipoprotein (LDL;
Disterer et al., 2013; Khoo et al., 2007). In this case, skip-
ping of exon 27 results in a premature stop codon in exon
28, thus leading to a truncated protein, APOB87 (Fig. 1B).
This imitates natural shortened APOB isoforms found in
familial hypobetalipoproteinemia, where LDL levels are
low because of increased LDL clearance and reduced LDL
assembly. In hypercholesterolemic human APOB trans-
genic mice, generation of relatively low levels of skipped
APOB87 (6.8%) was shown to reduce LDL cholesterol by
34–51% (Disterer et al., 2013).
A related option is to alter the balance between a full-
length isoform and a naturally occurring splice form with a
different function. One way to achieve this is to induce al-
ternative polyadenylation via inclusion of an intron contain-
ing polyadenylation sites into the mRNA. For example, the
kinase insert domain receptor (KDR; Uehara et al., 2013) is a
membrane-bound vascular endothelial growth factor (VEGF)
receptor with a soluble isoform that lacks an intracellular
tyrosine kinase domain. This is due to inclusion of intron 13,
which contains a stop codon and two polyadenylation sites
that are subsequently used and thus result in a shortened
mRNA with exons 14–30 excluded (Fig. 1C). The soluble
isoform naturally occurs in human cornea, still binds VEGF,
but is functionally inactive, and has been shown to prevent
lymphangiogenesis in this tissue. Uehara and colleagues
show that a phosphorodiamidate morpholino oligonucleotide
(PMO) increased the soluble isoform in vitro and suppressed
hemangiogenesis and lymphangiogenesis after laser photo-
coagulation or corneal suture as well as reducing graft re-
jection after transplantation in mouse models.
This principle is also applicable to other receptor tyrosine
kinases (Vorlova´ et al., 2011). For instance, Fms-related
tyrosine kinase 1 (FLT1) is another membrane-bound vas-
cular endothelial growth factor with similar structure. Again,
PMOs can be used to influence the ratio of the membrane-
bound and soluble isoforms through inclusion of intron 13
into the mRNA (Owen et al., 2012). Increases in the soluble
FLT1 isoform are shown to decrease choroidal neovascu-
larization after laser injury. This also induced tumor regres-
sion in a human breast adenocarcinoma xenograft mouse
model. Soluble FLT1 and KDR therefore represent important
drug targets in cancer metastasis.
Another important target in cancer is the signal transducer
and activator of transcription 3 (STAT3) protein. Here, two
isoforms exist. The full-length a form can be activated by
phosphorylation at two key amino acids (tyrosine-705 and
serine-727), causing dimerization and subsequent translocation
to the nucleus, where binding to its target promoter sequences
induces gene expression. The truncated STAT3b isoform is
generated when an alternative acceptor site in exon 23 is used
and thus lacks the C-terminal transactivation domain, includ-
ing the serine-727 phosphorylation site necessary to induce
transcription, but can still bind to its target promoters (Fig. 1D).
Redirection of splicing from the STAT3a to the STAT3b
isoform prompts apoptosis in cancer cells and inhibits tumor
growth in a xenograft model (Zammarchi et al., 2011).
SSOs can also be used to reduce aberrant splice forms,
preferentially expressing an isoform that diminishes damage
done by loss of the correct full-length isoform due to a
splice site mutation (Gedicke-Hornung et al., 2013). The
authors described an mRNA variant (variant 4; Var-4) of
cardiac myosin-binding protein-C (Mybpc3), with in-frame
deletions of exons 5 and 6. Redirection of splicing away
from the three aberrant mRNAs, missense Mut-1 and out-of-
frame Mut-2 and - 3, toward increased expression of the
Var-4 RNA isoform was shown to restore cardiac function
and prevent left ventricular hypertrophy in a mouse model
of hypertrophic cardiomyopathy. For efficient delivery to
the heart, the authors developed an adeno-associated virus
serotype 9 (AAV9) vector with the splice-switching oligo-
nucleotides embedded in modified U7 small nuclear RNA
(U7 snRNA) (Goyenvalle et al., 2004). The modification
directs the normally nonspliceosomal U7 snRNA to the
spliceosome, thus delivering the inserted oligonucleotide to
the proper subcellular localization.
Another innovative application of splicing modulation
addresses the problem of exon trapping caused by inherited
SINE-VNTR-Alu (SVA; SINE, short interspersed elements;
VNTR, variable number of tandem repeats) retrotransposon
insertions (Taniguchi-Ikeda et al., 2011; Fig. 1E). This ret-
rotransposon contains a strong 3¢ splice site. Taniguchi-
Ikeda and colleagues demonstrated that insertion of this
retrotransposon was responsible for abnormal splicing in the
fukutin (FKTN) gene leading to Fukuyama muscular dys-
trophy. Correction of the anomalous splicing pattern, using
SSOs targeted to the 3¢ splice site within the SVA, partially
rescued normal fukutin expression and function in a mouse
model and also in patient-derived cells. In addition, they
590 DISTERER ET AL.
T
a
b
l
e
1
.
N
e
w
T
h
e
r
a
pe
u
t
ic
A
pp
l
ic
a
t
io
n
s
fo
r
S
pl
ic
e
-S
w
it
c
h
in
g
O
l
ig
o
n
u
c
l
e
o
t
id
e
s
A
u
th
o
r
T
a
rg
et
g
en
e
D
is
ea
se
S
h
o
rt
d
es
cr
ip
ti
o
n
T
a
rg
et
S
S
O
le
n
g
th
a
n
d
ch
em
ic
a
l
m
o
d
ifi
ca
ti
o
n
s
D
is
te
re
r
et
a
l.
(2
0
1
3
)
A
P
O
B
F
am
il
ia
l
h
y
p
er
ch
o
le
st
er
o
le
m
ia
S
k
ip
p
in
g
o
f
ex
o
n
2
7
to
p
ro
d
u
ce
tr
u
n
ca
te
d
A
P
O
B
8
7
is
o
fo
rm
an
d
re
d
u
ce
p
la
sm
a
L
D
L
-c
h
o
le
st
er
o
l
In
tr
o
n
2
6
B
P
,
P
P
T
,
3
¢
sp
li
ce
si
te
+
in
tr
o
n
2
7
5
¢s
p
li
ce
si
te
5
0
-m
er
;
2
¢-M
e
w
it
h
p
ar
ti
al
P
S
o
n
5
¢a
n
d
3
¢e
n
d
s
U
eh
ar
a
et
a
l.
(2
0
1
3
)
K
D
R
L
as
er
-i
n
d
u
ce
d
ch
o
ro
id
al
n
eo
v
as
cu
la
ri
za
ti
o
n
;
co
rn
ea
l
g
ra
ft
re
je
ct
io
n
S
w
it
ch
b
et
w
ee
n
m
em
b
ra
n
e
b
o
u
n
d
(p
ro
h
em
an
g
io
g
en
ic
)
an
d
so
lu
b
le
K
D
R
(a
n
ti
ly
m
p
h
an
g
io
g
en
ic
)
is
o
fo
rm
s
E
x
o
n
1
3
+
in
tr
o
n
1
3
5
¢
sp
li
ce
si
te
2
5
-m
er
;
P
M
O
,
V
iv
o
-P
M
O
G
ed
ic
k
e-
H
o
rn
u
n
g
et
a
l.
(2
0
1
3
)
M
Y
B
P
C
3
H
y
p
er
tr
o
p
h
ic
ca
rd
io
m
y
o
p
at
h
y
In
cr
ea
se
in
v
ar
ia
n
t-
4
m
R
N
A
an
d
re
d
u
ct
io
n
o
f
o
th
er
ab
er
ra
n
t
m
R
N
A
s
to
ab
o
li
sh
ca
rd
ia
c
d
y
sf
u
n
ct
io
n
an
d
p
re
v
en
t
le
ft
v
en
tr
ic
u
la
r
h
y
p
er
tr
o
p
h
y
E
S
E
in
ex
o
n
s
5
an
d
6
2
5
-m
er
;
2
¢-M
e-
P
S
,
A
A
V
-U
7
-S
S
O
L
en
tz
et
a
l.
(2
0
1
3
)
U
S
H
1
C
U
sh
er
sy
n
d
ro
m
e
C
o
rr
ec
ti
o
n
o
f
d
ef
ec
ti
v
e
sp
li
ci
n
g
in
m
u
ta
te
d
U
S
H
1
C
.2
1
6
G
>
A
to
re
sc
u
e
co
ch
le
ar
h
ai
r
ce
ll
s,
v
es
ti
b
u
la
r
fu
n
ct
io
n
,
an
d
h
ea
ri
n
g
C
ry
p
ti
c
5
¢s
p
li
ce
si
te
ca
u
se
d
b
y
m
u
ta
ti
o
n
1
8
-m
er
;
2
¢-M
O
E
-P
S
T
an
ig
u
ch
i-
Ik
ed
a
et
a
l.
(2
0
1
1
)
F
K
T
N
F
u
k
u
y
am
a
co
n
g
en
it
al
m
u
sc
u
la
r
d
y
st
ro
p
h
y
P
re
v
en
ti
o
n
o
f
p
at
h
o
g
en
ic
ex
o
n
tr
ap
p
in
g
ca
u
se
d
b
y
re
tr
o
tr
an
sp
o
so
n
to
re
sc
u
e
n
o
rm
al
fu
k
u
ti
n
M
ix
o
f
S
S
O
s
ta
rg
et
in
g
ab
er
ra
n
t
IS
E
,
3
¢
sp
li
ce
si
te
an
d
E
S
E
2
5
-m
er
;
2
¢-M
e-
P
S
,
V
iv
o
-P
M
O
O
w
en
et
a
l.
(2
0
1
2
)
F
L
T
1
L
as
er
-i
n
d
u
ce
d
ch
o
ro
id
al
n
eo
v
as
cu
la
ri
za
ti
o
n
S
w
it
ch
b
et
w
ee
n
m
em
b
ra
n
e-
b
o
u
n
d
an
d
so
lu
b
le
F
L
T
1
(i
n
h
ib
it
o
r
o
f
V
E
G
F
-A
-m
ed
ia
te
d
an
g
io
g
en
es
is
)
E
x
o
n
1
3
+
in
tr
o
n
1
3
5
¢s
p
li
ce
si
te
2
5
-m
er
;
P
M
O
,
V
iv
o
-P
M
O
Z
am
m
ar
ch
i
et
a
l.
(2
0
1
1
)
S
T
A
T
3
C
an
ce
r
S
w
it
ch
b
et
w
ee
n
S
T
A
T
3
a
an
d
S
T
A
T
3
b
(p
ro
ap
o
p
to
ti
c)
E
x
o
n
2
3
3
¢
sp
li
ce
si
te
+
E
S
E
2
3
-m
er
;
P
M
O
,
V
iv
o
-P
M
O
O
so
ri
o
et
a
l.
(2
0
1
1
)
L
M
N
A
H
u
tc
h
in
so
n
-
G
il
fo
rd
p
ro
g
er
ia
C
o
rr
ec
ti
o
n
o
f
d
ef
ec
ti
v
e
sp
li
ci
n
g
in
m
u
ta
te
d
L
M
N
A
.
1
8
2
4
C
>
T
,
w
h
ic
h
le
ad
s
to
tr
u
n
ca
te
d
L
M
N
A
(p
ro
g
er
in
)
ex
p
re
ss
io
n
M
ix
o
f
S
S
O
s
ta
rg
et
in
g
ex
o
n
1
0
la
m
in
A
sp
li
ce
d
o
n
o
r
si
te
+
cr
y
p
ti
c
5
¢s
p
li
ce
si
te
in
ex
o
n
1
1
ca
u
se
d
b
y
m
u
ta
ti
o
n
2
5
-m
er
;
P
M
O
,
V
iv
o
-P
M
O
2
¢-M
e,
2
¢-O
-m
et
h
y
l
o
li
g
o
ri
b
o
n
u
cl
eo
ti
d
e;
2
¢-M
O
E
,
2
¢-O
-m
et
h
o
x
y
et
h
y
l
o
li
g
o
ri
b
o
n
u
cl
eo
ti
d
e;
A
A
V
,
ad
en
o
-a
ss
o
ci
at
ed
v
ir
u
s;
A
P
O
B
,
ap
o
li
p
o
p
ro
te
in
B
;
B
P
,
b
ra
n
ch
p
o
in
t
se
q
u
en
ce
;
E
S
E
,
ex
o
n
ic
sp
li
ce
en
h
an
ce
r;
IS
E
,
in
tr
o
n
ic
sp
li
ce
en
h
an
ce
r;
K
D
R
,
k
in
as
e
in
se
rt
d
o
m
ai
n
re
ce
p
to
r/
v
as
cu
la
r
en
d
o
th
el
ia
l
g
ro
w
th
fa
ct
o
r
re
ce
p
to
r
2
;
L
D
L
,
lo
w
-d
en
si
ty
li
p
o
p
ro
te
in
;
L
M
N
A
,
la
m
in
A
;
P
M
O
,
p
h
o
sp
h
o
ro
d
ia
m
id
at
e
m
o
rp
h
o
li
n
o
o
li
g
o
n
u
cl
eo
ti
d
e;
P
P
T
,
p
o
ly
p
y
ri
m
id
in
e
tr
ac
t;
P
S
,
p
h
o
sp
h
o
ro
th
io
at
e;
S
S
O
s,
sp
li
ce
-s
w
it
ch
in
g
o
li
g
o
n
u
cl
eo
ti
d
es
;
S
T
A
T
,
si
g
n
al
tr
an
sd
u
ce
r
an
d
ac
ti
v
at
o
r
o
f
tr
an
sc
ri
p
ti
o
n
;
V
E
G
F
,
v
as
cu
la
r
en
d
o
th
el
ia
l
g
ro
w
th
fa
ct
o
r;
V
iv
o
-P
M
O
,
o
ct
ag
u
an
id
in
e-
co
n
ju
g
at
ed
P
M
O
.
591
showed that exon trapping by an SVA is also present in
patients with autosomal recessive hypercholesterolemia or
neutral lipid storage disease. Insertion of an SVA has
also been implicated in hereditary elliptocytosis, X-linked
agammaglobulinemia, neurofibromatosis type 2, and X-
linked dystonia-parkinsonism, suggesting that SSOs would
be appropriate therapeutic reagents for treatment of these
diseases (Taniguchi-Ikeda et al., 2011).
More straightforward correction of aberrant splicing
patterns has been described in the Usher syndrome 1C
(USH1C; Lentz et al., 2013) and laminin A (LMNA; Osorio
et al., 2011) genes, both examples caused by mutations that
lead to activation of cryptic splice sites. At present, there is
no cure for either Usher syndrome or Hutchinson-Gilford
progeria, rare but devastating genetic disorders. The out-
come of these studies bodes well for future clinical devel-
opment, particularly with the increased funding and interest
in treatment of rare diseases.
Measuring the Efficiency
of Splice-Switching Oligonucleotides
It is of concern, however, that the majority of publications
rely on quantitative measurement of splice forms using re-
verse transcription and PCR. It remains common practice to
use one primer set to amplify both mRNA variants of interest,
even though it is well established that shorter PCR products
amplify better than longer products in the same reaction
(Walsh et al., 1992). Hence, as the skipped or truncated
isoform is generally shorter, the efficiency of splice modu-
lation will be overestimated. Also, relative quantification of
end-point PCR products is not appropriate, as the distinct
amplification efficiencies between long and short products
result in reaching the plateau phase at different times.
Therefore, relative quantification of the two isoforms will
vary depending on the amount of template input and PCR
cycle number. Using radioactive PCR may improve the rel-
ative quantification of two bands on a gel compared with
ethidium bromide-based detection, but does not address
the underlying problem. To overcome these problems, we
have developed a fully validated real-time quantitative PCR
(RT-qPCR) assay and illustrate its value in measuring SSO-
mediated truncation of APOB100 (Fig. 2). Here, the exon 27-
skipping efficiency for SSO 3B, using a radioactive end-point
PCR assay (Khoo et al., 2007), is significantly higher than
when measured by the validated RT-qPCR assay (Disterer
et al., 2013), indicating that the earlier assay was positively
biased in its assessment of the skipped isoform.
To date, in other splice-switching studies where RT-
qPCR is described, only one nonvalidated reference gene
has been used and requisite minimal essential information
(Bustin et al., 2009) is lacking. However, accurate relative
quantification by RT-qPCR can easily be achieved with
careful primer design and separate PCRs for each isoform,
as long as a common standard curve is used, derived from a
plasmid carrying both PCR amplification products (Fig. 3;
Disterer and Khoo, 2012; Disterer et al., 2013).
SSO Toxicity, Chemistry, and Sequence Selection
Two publications have reviewed SSO chemistry in detail
(Saleh et al., 2012; Jarver et al., 2014), so here we provide
only a short summary and then focus on a synergistic view of
the interplay between sequence selection, chemistry, and
toxicity. As is apparent from Table 1, the most commonly
used SSO chemical modifications are 2¢-O-methyl RNA with
phosphorothioate substitutions on the ribose backbone (2¢-
Me-PS) and phosphorodiamidate morpholino oligonucleo-
tides (PMOs). Oligonucleotides with 2¢-Me-PS modifications
are commercially available from several oligonucleotide
manufacturers, whereas PMOs are sold exclusively by Gene
Tools (Philomath, OR) and limited to a maximum length of
30 bases. Two other modifications in common use are 2¢-O-
methoxyethyl oligoribonucleotides (2¢-MOE-PS) and locked
nucleic acids (LNAs). Use of the former is limited by avail-
ability, as Isis Pharmaceuticals owns the technology and
currently no commercial supplier has a licence for produc-
tion. LNAs are available from Exiqon (Vedbaek, Denmark),
but if the Exiqon proprietary algorithm for optimal posi-
tioning of the LNA-modified bases within the SSO is re-
quested their location is not transparent to the user.
Toxicities associated with these chemical modifications
are well characterized by now. Subcutaneous administration
of unprotected 2¢-Me-PS causes injection site reactions,
proteinuria, elevated urinary a1-microglobulin levels (Goe-
mans et al., 2011), and, in some cases, transient thrombo-
cytopenia (Aartsma-Rus and Muntoni, 2013). The eteplirsen
phase 2 trial extension suggests a better safety profile for
PMOs, with no serious side effects reported in comparison
with placebo, but the small number of participants makes
evaluation difficult (Mendell et al., 2013). Sarepta Ther-
apeutics states that no serious side effects were seen in more
than 400 patients treated with PMOs as part of their antiviral
program. However, although so far there are no dose-lim-
iting toxicities in patients treated with PMO, studies com-
paring rodents, nonhuman primates, and humans suggest
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FIG. 2. Comparison between radioactive end-point PCR
and validated RT-qPCR assay. In both cases, HepG2 cells
were transfected with 250 nM SSO 3B (SSO 1 in Disterer
et al., 2013) for 48 hr, using Lipofectamine 2000 (Life
Technologies) according to the manufacturer’s instructions.
Khoo and colleagues (2007) reported a skipping percentage
of 11.13– 0.97% (n = 3), using a radioactive end-point PCR
assay, whereas Disterer and colleagues (2013) achieved
4.33 – 0.61% (n = 15) with a fully validated RT-qPCR assay.
Downstream RNA purification, reverse transcription, and
PCR conditions varied slightly, but should not have caused
such a consistent difference. Values represent means – SEM
from independent experiments as calculated with GraphPad
Prism 5 (GraphPad Software).
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that the same PMO (mg/kg) dose is needed for each, making
patient therapy exceedingly expensive.
Oligonucleotides with 2¢-MOE-PS modifications are vari-
ously reported to be more effective with fewer proinflam-
matory consequences than 2¢-Me-PS (Hua et al., 2010; Yang
et al., 2013), but even so, clinical trials with oligonucleotides
containing 2¢-MOE-PS modifications such as mipomersen
have shown that injection site and possibly influenza-like re-
actions remain a problem (Raal et al., 2010). Long-term
studies in DMD using 2¢-Me-PS SSOs have shown little evi-
dence of inflammation, suggesting that preclinical toxicology
may pick up species-specific sensitivities that may not apply to
humans (Frazier et al., 2013). LNA-containing SSOs were
found to be more effective than 2¢-MOE-PS-modified oligo-
nucleotides (Swayze et al., 2007), but are also associated with
significant liver (Swayze et al., 2007) and kidney toxicity (van
Poelgeest et al., 2013). Progress in elucidating toxicity
mechanisms has been made by reducing the length of LNA
oligonucleotides (Seth et al., 2009).
Although the case can be made that toxicity of SSOs is
driven mostly by their chemistry, for RNase H-activating
LNA antisense oligonucleotides there is an association be-
tween particular sequence elements and toxicity (Hagedorn
et al., 2013). Clearly, it is important to know whether there
is sequence-dependent toxicity, because of its influence on
SSO target design, although the extent to which SSO se-
quences can be modified is restricted by the availability of
susceptible pre-mRNA target sequences. A second and not
so obvious issue is that if toxicities are generic to oligonu-
cleotide chemistry, it would be much easier to develop SSO-
based therapies as regulatory authorities might be persuaded
to approve new therapies on the basis of previous preclinical
toxicology using older therapies. In this respect, we would
encourage companies involved in developing splice modu-
lation therapies to publish more of their preclinical data, at
least regarding chemistry and sequence-associated toxicities
of oligonucleotides that were not taken into the clinic.
Software prediction tools such as RNAstructure, mfold
(Zuker, 2003), and Human Splicing Finder (Desmet et al.,
2009) can be incredibly useful in designing SSOs with a
high likelihood of effectiveness. General recommendations
for SSO sequence design and a step-by-step guide for exon-
internal SSOs are shown in Fig. 4 (adapted from Aartsma-
Rus, 2012). Although targeting exonic splice enhancer sites
close to the 3¢ splice site seems the most promising avenue,
this strategy is not always successful in the context of other
exons such as APOB exon 27 (Khoo et al., 2007; Disterer
et al., 2013). The 3¢ and 5¢ splice sites should not be over-
looked and are often used successfully (Table 1). It is also
worth considering bipartite (Khoo et al., 2007; Peacey et al.,
2012) or tripartite SSOs (Incitti et al., 2010; Disterer et al.,
2013; P. Disterer et al., unpublished data) that combine sev-
eral intronic and/or exonic target sites as these can markedly
increase the efficiency of exon skipping.
Sometimes it is necessary to go even further afield from
the actual exon to be excluded or included. For example,
26 28
APOB exon 27 skipped mRNA
AATATGAACTAAATGGGAATGGGAA
171 bp sk PCR product
Standard
plasmid
26 27 28
APOB full-length mRNA
GAACTAAATGTTTTGGGAACAC
281 bp fl PCR product
dilution
U
107
U
106
U
108
U
105
U
104
U
103
U
102
copies per reaction
Serial UU
? ?
Cq
Cq
full-length
PCR
skipped
PCR
FIG. 3. RT-qPCR assay for accurate determination of skipping efficiency. Specific primers for the detection of apoli-
poprotein B (APOB) full-length and exon 27-skipped mRNA isoforms are designed (left, top and bottom; exon 27- and exon
28-specific sequences are in red and underscored). The resulting full-length (fl) and skipped (sk) PCR products are cloned
into a plasmid (left, middle), which is then serially diluted to produce one standard curve (right, middle). This standard curve
is used in both the full-length and skipped PCRs to quantify the copy number per reaction for both isoforms (right, top and
bottom). As the standard plasmid contains only one copy each of the full-length and skipped PCR products, copy number
per reaction results obtained from the two qPCRs can be directly related to each other without the need for reference gene
normalization. Thus, the efficiency of skipping can be expressed as a percentage, using the following calculation:
sk/(fl + sk) · 100. For example, for the blue unknown sample (left thick line in the PCR amplification plots), if copy number
per reaction for the full-length PCR is 8 · 106 and for the skipped it is 2 · 106, then the skipping percentage would be 20%.
The red unknown sample (right thick line in the PCR amplification plots) represents an untreated control with skipping
percentage< 0.01 (fl=4·106; sk=4·102). Cq, quantification cycle. Color images available online at www.liebertpub.com/hum
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exon inclusion of SMN2 exon 7 was most efficient with
SSOs targeting an intronic negative splice regulator se-
quence (ISS-N1), which is located 10 bases downstream of
the SMN2 intron 7 5¢ splice site (Singh et al., 2006; Hua
et al., 2008). Targeting intronic structures formed by long-
distance interactions up to 300 nucleotides from the exon-
intron junction can also be a successful strategy (Singh
et al., 2013). Moreover, it is not yet clear whether there are
separate design rules or optimal target regions for consti-
tutively included exons, compared with exons that naturally
undergo some degree of alternative splicing.
In light of these data, we recommend initial screening of
SSOs designed according to the guidelines proposed by
Aartsma-Rus (2012), with some additional SSOs targeted to
the splice donor and acceptor sites. If these SSOs do not
result in highly efficient splicing, combining partially ef-
fective oligonucleotides into bipartite or tripartite SSOs
should be considered. If this still does not yield efficient
splice modulation, exploration of the intron sequence and
structure context can be attempted; however, this is time-
consuming and technically challenging.
Another important point when designing SSOs is that of
sequence specificity and potential off-target effects. In-
tronic splice site sequences are more similar across all
genes than exonic sequences, but all candidate SSOs
should be evaluated for off-target binding by performing a
BLAST search during the design stage and, after selection
of leads, by experimental assays such as exon arrays or
RNA-seq (P. Disterer et al., unpublished data). It is also
noteworthy that theoretically SSOs targeting exon-only
sequences can be sequestered by cytosolic mRNA mole-
cules, especially if the target gene is highly expressed. If
so, a higher dose will be required to induce splice switching
in nuclear pre-mRNA.
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Calculate free energy of SSO 
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SSO to target: dG of exon - dG 
of target–SSO complex (21-28)
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Select best SSOs and analyse 
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secutive homologous nts)
Step 8
FIG. 4. Development of candidate
SSOs: step by step (adapted from
Aartsma-Rus, 2012). The following
general rules increase the chances of
successful SSO development. Step 1:
Model the secondary structure of the
target exon including*50 nucleotides
upstream and downstream, using
mfold (here APOB exon 27). Choose
the two or three energetically most
stable secondary structures or use the
ss-count output to detect partially
closed or accessible regions of *20–
30 nucleotides. Steps 2 and 3: Use
Human Splice Finder to analyze ex-
onic splice silencer (ESS, red) and
exonic splice enhancer (ESE, green,
darker shades = stronger sites) clusters.
Binding sites of serine/arginine-rich
splicing factors (SFRS) such as SRp55
(light green), SF2/ASF (medium
green), SC35 (dark green), or SRp40
(black) are good targets, whereas het-
eronuclear ribonucleoprotein (hnRNP)
suppresses splicing. Design *20-mer
SSOs, preferably at the 5¢ end of the
exon, without stretches of three or
more Gs or Cs that bind to these
regions. Step 4: Analyze the melting
temperature Tm ( > 48C) and GC
content (40–60%) of proposed SSOs
(reverse complement of the target se-
quence). Step 5: If either value is too
low or too high, increase or decrease
the SSO length. Step 6: Calculate the
free energy (dG) of the proposed
SSO (for 20-mer SSOs it should be 0
to - 4) and SSO–SSO homodimers
(up to - 15), using RNAstructure.
Step 7: Calculate the dG of SSO
bound to the target exon (between 21
and 28). Step 8: Analyze proposed
SSO, using BLAST; stretches of 15 or
more consecutive homologous nucle-
otides should be avoided. Color images
available online at www.liebertpub
.com/hum
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The previous considerations assume, of course, that SSOs
bind only to completely matched antisense sequences. An
early study found that exon skipping was completely abor-
ted when using mismatch-containing 2¢-Me-PS SSOs, but
this was not invariant as PMO-modified SSOs with or
without two mismatches to the target sequence had equal
efficiencies (Heemskerk et al., 2009). Permissiveness is also
reported for SSOs modified with LNA (Aartsma-Rus et al.,
2004). In addition, Fragall and colleagues (2011) found that
a 2¢-Me-PS SSO perfectly matching the genomic DNA se-
quence in control cells showed paradoxically increased
skipping efficiency in patient cells containing a single base
insertion in the genomic sequence. However, this increase in
efficiency could reflect escape of the skipped patient mRNA
from nonsense-mediated decay due to the now-corrected
reading frame. It appears, therefore, that the type of SSO
chemical modification may influence off-target effects dur-
ing later stages of therapeutic development. In particular,
the drive to use high-affinity chemistries such as LNA may
in fact enable off-target effects because of their ability to
hybridize even with mismatches, and this issue should be
borne in mind when selecting the chemistry to be used.
Pharmacokinetics of SSOs
Extended pharmacokinetics is a desirable quality for SSO
therapeutics, especially where chronic treatment is envis-
aged, but varies widely between SSOs constructed on the
basis of different chemistries. Phosphorothioate oligonu-
cleotides are characterized by their binding to serum pro-
teins, particularly albumin and a2-macroglobulin. This leads
to an extended half-life as renal elimination is reduced.
Distribution to tissues is also rapid, with half-lives typically
< 1 hr. Once distribution is complete, the terminal elimina-
tion half-life is extended to 40–60 hr or longer and is largely
determined by degradation of the oligonucleotides within
the tissue (Crooke, 2004). 2¢-MOE-PS-based oligonucleo-
tides are similarly rapidly distributed to tissues and then
have extended terminal elimination half-lives of 20–34 days
(Yu et al., 2009). On the other hand, the neutral backbone of
PMOs precludes binding by serum proteins, and they par-
tition into tissues to a lesser extent than 2¢-Me-PS SSOs
(Heemskerk et al., 2009). ‘‘Plain’’ PMOs are eliminated
relatively quickly with half-lives of 1–20 hr as PMOs are
unable to bind serum proteins and are therefore eliminated
by renal filtration (Amantana and Iversen, 2005). However,
if PMOs are able to distribute into tissues, for example by
coupling to cell-penetrating peptides, their elimination half-
life is greatly extended as PMOs themselves are extremely
stable biologically (Amantana et al., 2007). Therefore, three
key determinants of SSO pharmacokinetics emerge, namely,
(1) their ability to persist in the circulation (largely deter-
mined by their resistance to renal elimination), (2) their
ability to partition rapidly into tissues, and (3) their resis-
tance to degradation in peripheral tissues, as opposed to
plasma. These factors influence the selection of chemistries
for different SSOs.
SSO Chemistry and Tissue Delivery
Oligonucleotide chemistry is also associated with slightly
different tissue tropism when systemic delivery is used. For
example, LNAs distribute mainly to the kidney, liver, colon,
and small intestine (Roberts et al., 2006). PMO SSOs do not
bind to plasma proteins and as a result tend to be eliminated
quickly through renal filtration, although they can distribute
to most tissues in the body (Sazani et al., 2002). As indi-
cated previously, 2¢-Me-PS- and 2¢-MOE-PS-modified SSOs
bind to plasma proteins through their negative charge and
thus accumulate mainly in the kidney and liver, with low
levels partitioning into other tissues such as spleen and
muscle (Sazani et al., 2002; Heemskerk et al., 2010).
However, 80% of SSO uptake in the liver is mediated by
Kupffer reticuloendothelial cells and only 20% reaches the
hepatocytes.
Widespread tissue distribution of SSOs after systemic
administration may result in undesirable effects if the target
pre-mRNA is also expressed in other tissues. For example,
the full-length APOB gene is expressed in liver to produce
APOB100 protein, whereas in the intestine the RNA-edited
isoform APOB48 is expressed to initiate chylomicron syn-
thesis for the transport of dietary fat and fat-soluble vita-
mins. Interference with chylomicron assembly, by inhibitors
of microsomal triglyceride transfer protein, results in fat and
vitamin K malabsorption (Cuchel et al., 2013). This unde-
sirable side effect was evident when using small interfering
RNA (siRNA) to knock down APOB mRNA and reduce
plasma LDL, as chylomicron levels were reduced by 50%
(Soutschek et al., 2004), but is not an issue when using SSO
to generate APOB87 mRNA, as this can also undergo in-
testinal RNA editing to allow normal APOB48 expression
(Disterer et al., 2013).
Our own data suggest a correlation between target ex-
pression levels, the requisite SSO dose, and efficient deliv-
ery to the nucleus for effective splicing manipulation. For
instance, we were unable to achieve significant exon 27
skipping of hepatic human APOB in transgenic mice with
systemic delivery via tail vein injection at doses up to
25mg/kg (Disterer et al., 2013). Hydrodynamic injections
(25mg/kg) of fluorescence-labeled SSO increased hepatic
delivery slightly, but led to only marginal increases in
skipping efficiency (<1.6%). In this mouse model, expres-
sion of the human APOB transgene is about five times
higher than that of murine Apob, which itself is already
expressed at a high level (19710.48 units according to
BioGPS; Wu et al., 2012). Significant skipping efficiency
was achieved only with the SSO complexed to a liver-
directed delivery reagent, Invivofectamine 2.0 (IVF2.0; Life
Technologies) (Disterer et al., 2013), which significantly
increased delivery of fluorescent SSO. This effect was in-
dependent of the SSO sequence (Disterer et al., unpublished
data). These findings are comparable to those of Yilmaz-
Elis and colleagues (2013), who reported 90% exon skip-
ping of interleukin-1 receptor accessory protein (Il1rap)
after a single tail vein injection of a 21-mer SSO complexed
to IVF2.0 (10mg/kg per mouse), whereas four daily injec-
tions of SSO alone at 100mg/kg each were needed to induce
*50% exon skipping. The relative BioGPS expression va-
lue is 8.63 for Il1rap in murine liver, indicating that high
doses of SSOs are still required even for genes expressed at
relatively low levels. The systemic delivery of SSO leading
to SMN2 exon 7 inclusion in a mouse model of SMA re-
sulted in up to 70% efficiency in liver (Hua et al., 2011).
However, two subcutaneous injections of up to 160mg/kg, a
total dose of 320mg/kg, were necessary to achieve this
DEVELOPING THERAPEUTIC SSOs 595
efficiency. Like Il1rap, Smn is expressed at low levels in
mouse liver (BioGPS expression value, 21.74).
The emerging evidence suggests that when targeting low-
expressed RNAs, systemic delivery of high doses is suffi-
cient to induce effective splice modulation, at least in an
easily accessible tissue such as the liver. However, splice
modulation of highly expressed pre-RNAs or in a difficult-
to-access tissue would require prohibitively expensive and
potentially toxic SSO doses to achieve high efficiency when
using systemic delivery. Effective and selective SSO de-
livery to the nucleus of the tissue of interest is of paramount
importance to increase potency and to reduce possible ad-
verse effects. This may well necessitate the use of delivery
reagents in various forms, including conjugates with cell-
targeting ligands, cell-penetrating peptide conjugates, and
nanoparticle carrier formulations. These have been devel-
oped mostly for siRNA applications, but can be equally
useful for SSO delivery ( Juliano et al., 2008). It is clear that
future SSO therapies will need to use both specific and
tailored delivery technologies to obtain the key benefits of
increased potency and reduced toxicity.
Conclusions
Up to 50% of human genetic diseases are caused by
mutations that affect splicing, and therefore therapeutic
modulation of the process, using synthetic SSOs, is emerg-
ing as a promising alternative to conventional gene addition
technologies. Like gene therapy and antibody- or antisense-
based treatments before it, there is a certain boom and bust
cycle to the development of splicing therapeutics. Today,
perhaps, the field is in a low period with the failure of the
drisapersen phase 3 trial and the 2013 FDA rejection of
accelerated approval for eteplirsen. However, new guidance
from the FDA regarding the possibility of accelerated ap-
proval for eteplirsen and the success of ISIS-SMNRx in early
trials gives hope for another upward swing and conceivably
presages a sustained period of notable progress on several
fronts. Solving effective targeted delivery is currently the
most important challenge facing the field of splicing mod-
ulation and, we suspect, most likely underlies the drisa-
persen failure.
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